-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Innovation Ranking
NewInnovation Ranking – IDT Corp
IDT Corp (IDT) is a telecommunication service provider that offers mobile application development and telecommunication services. The company provides services such as consumer, business services among others. IDT also provides bundled local and long distance phone services, including unlimited local, regional toll, and domestic long distance calling, and calling features to residential customers. It manages receivables portfolios and performs debt collection services. The company offers voice termination through various service levels, providing carriers and resellers.Ity markets its products under the...
-
Sector Analysis
Contract Pharmaceutical Dose Manufacturing Industry – Composition, Size, Market Share and Outlook, 2023 Edition
Contract Pharmaceutical Dose Manufacturing Industry Overview The total dose CMO contract revenue in 2022 represented significant growth over 2021 revenue. The growth rate was the highest recorded since 2011 for commercial contract dose manufacturing revenues, and surprisingly adds to the strong growth experienced in 2021, despite demand for COVID-19 vaccines and therapies waning in 2022. The Contract Pharmaceutical Dose Manufacturing Industry report is a comprehensive look at the finished dose contract manufacturing landscape in 2023. It includes an analysis of...
-
Company Insights
Innovation and Patenting activity of IDT Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of IDT Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Blood Pressure Monitors Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Blood Pressure Monitors Pipeline Market Overview Blood pressure monitors include blood pressure transducers. It converts blood pressure into electrical signals and sphygmomanometers, a device consisting of a pressure gauge and a rubber cuff that wraps around the upper arm and wrist which inflates to constrict the arteries and measure the blood pressure. The Blood Pressure Monitors pipeline market research report provides comprehensive information about the pipeline products with a comparative analysis of the products at various stages of development and...
-
Company Profile
IDT Corp – Company Profile
IDT Corp (IDT) is a telecommunication service provider that offers mobile application development and telecommunication services. The company provides services such as consumer and business services among others. IDT also provides bundled local and long distance phone services, including unlimited local, regional toll, and domestic long distance calling, and calling features to residential customers. It manages receivables portfolios and performs debt collection services. The company offers voice termination through various service levels, providing carriers and resellers. It markets its products...
Add to Basket -
Sector Analysis
Contract Injectable Packaging Trends in the Bio/Pharma Industry
Injectables and their packaging requirements are very important to marketed treatments given the volume of vaccines required to tackle the COVID-19 pandemic and the rising number of biologics in development pipelines and on the market. Most injectable drugs in the development pipeline are biologics, which will become increasingly approved and more established in the treatment landscape in the future. The top contract packaging organizations (CPOs) for injectables by the number of contracts are standalone packagers along with large CMOs which...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...
-
Sector Analysis
COVID-19: Contract Pharmaceutical Development and Manufacturing Relationships
This report examines contract manufacturing agreements for vaccines and therapies targeting COVID-19. It reports that there are more than 1,000 vaccines and therapies in development for COVID-19, and 36 vaccines and therapies approved (or granted emergency use authorization) for COVID-19 (as of report publication). At the beginning of the pandemic, slightly more than half of these agreements were for vaccines; this proportion has risen and continues to rise, as several vaccines have proven their safety and efficacy, received approval, and...
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...